Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Key to changes
?
Text removedfrom 2023 Q1- Text added to 2023 Q2
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. senior Avg
|
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. senior Avg
|
New words:
AARC, affirmative, androgen, antigen, ARRC, artificial, assembled, Baituowei, biased, carcinoembryonic, caspase, CEA, Chan, conjugate, constitutionality, controversial, dimer, downgrade, DualityBio, eighteen, Fast, flawed, follicular, goserelin, immediacy, intelligence, Julia, kicked, lab, learning, Lee, lender, lending, Lifirafenib, LSA, machine, mimetic, monomer, monotherapy, notably, obinutuzumab, overnight, poor, posted, prostate, QA, RAF, receivership, recession, regained, Relatedly, SMAC, SOFR, sonrotoclax, SSA, steering, Subscription, Surzebiclimab, susceptible, systematic, tasked, uncommitted, unresolved, unsecured, uphold, USA
Valuein 2023 Q1 filing- Value in 2023 Q2 filing
Original filings
Filing view